Strikingly, in in vivo preclinical experiments in patient-derived xenograft (PDX) murine models of AML with NPM1 mutation, the combinatorial HHT/ABT treatment with doses equivalent to the pharmacological concentrations, confirmed a strong synergistic anti-leukemic activity and gave a significant survival advantage compared with single drug or vehicle-treated animals [41]. Here, NPM1 is linked to acute myeloid leukemia.